Regeneron's Eylea last week scored an FDA nod for...

...the treatment of diabetic retinopathy, the leading cause of adult-onset blindness in the U.S. This new indication is a potential gamechanger for Regeneron, as Eylea could soon face generic competition from Novartis' brolucizumab in its strongest market, wet aged-related macular degeneration. For the treatment of macular edema, Eylea currently holds preferred status for 2% of covered lives, growing to 12% with step therapy and/or prior authorization. Overall, Eylea is covered in the pharmacy benefit for 30% of covered lives.

SOURCE: MMIT Analytics, as of 5/15/19